Insulin lispro protamine biosimilar(25R) (Gan & Lee)

精蛋白锌重组赖脯胰岛素生物类似药(25R)(甘李药业)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInsulin lispro protamine biosimilar(25R) (Gan & Lee)
Drug Alias Name精蛋白锌重组赖脯胰岛素混合注射液（25R）insulin lispro protamine suspension biosimilarprotamine/zinc/insulin lisproMixed Protamine Zinc Recombinant Human Insulin Lispro InjectionPrandilin25 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryMainland China
Original Approved Date2014/05/09
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGan & Lee Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesGan & Lee Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AB04A10AC04A10AD04
Related LinksN/A